A better comprehension of the molecular pathways involved in TGCC development, in particular the role of GPER/GPR30 in tumor progression, points out new tools like agonists or antagonists of GPER/GPR30, which could be used going forward by clinicians to target cancer cells and improve the patient’s chance of survival (68, 101). The gene discussed is GPER1; the disease is neoplasm.